OppenheimerFunds’s Ovid Therapeutics OVID Stock Holding History

OppenheimerFunds’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-424,580	Closed	-$2.41M	–	1846
2018 Q3	$2.41M	Sell	424,580 -90	-0%	-$682	﹤0.01%	875
2018 Q2	$3.31M	Buy	424,670 +500	+0.1%	+$4.29K	﹤0.01%	831
2018 Q1	$3M	Sell	424,170 -550	-0.1%	-$4.45K	﹤0.01%	818
2017 Q4	$4.19M	Hold	424,720	–	–	0.01%	823
2017 Q3	$3.64M	Sell	424,720 -280	-0.1%	-$2.33K	﹤0.01%	841
2017 Q2	$4.46M	Buy	+425,000	New	+$5.55M	0.01%	833

Other funds holding OVID

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

OppenheimerFunds's OVID Position: Q4 2018 in Review

OppenheimerFunds sold out of Ovid Therapeutics (OVID) in Q4 2018, closing a stake of 424,580 shares — an estimated $2.41M sold.

OppenheimerFunds first reported a position in OVID in Q2 2017 and held it in 6 quarters. The position peaked at $4.46M in Q2 2017. 47 funds tracked by Wall St. Rank hold OVID as of Q4 2018.

OppenheimerFunds reported no remaining Ovid Therapeutics position as of Q4 2018 after selling out during the quarter.
OppenheimerFunds sold 424,580 Ovid Therapeutics shares in Q4 2018, an estimated $2.41M.
OppenheimerFunds first reported a position in Ovid Therapeutics in Q2 2017 and held it in 6 quarters.
OppenheimerFunds's Ovid Therapeutics position peaked at $4.46M in Q2 2017.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2018.

Based on OppenheimerFunds's 13F filing for Q4 2018, filed 11 Feb 2019.